Actor portrayal
CNS Oncology
Reaching three of oncology’s hardest cancers.
Cerenome focuses entirely on some of the hardest cancers in oncology: recurrent glioblastoma, pediatric brain cancer, and leptomeningeal metastases. Survival in these cancers has barely improved in decades. Cerenome exists to change that, with diagnostics, treatments, and clinical intelligence these cancers have long gone without.
The Three CNS Cancers
Location matters more than tumor type.
Cancers affecting the central nervous system (CNS) can involve distinct anatomical compartments. Recurrent glioblastoma and the pediatric brain cancers Cerenome is studying primarily involve CNS tissue, while leptomeningeal metastases spread along the leptomeninges and through the cerebrospinal fluid. Together, these diseases reflect the different environments within the CNS that Cerenome is working to detect, treat, and better understand.
Magnified: The Brain’s Surface
Dura mater
Leptomeninges
Arachnoid + pia, with CSF between
Gray matter
White matter
CNS tissue
Recurrent glioblastoma
The most common primary brain tumor in adults.
CNS tissue
Pediatric brain cancer
The second most common cancer in children.
CSF & leptomeninges
Leptomeningeal metastases
Cancer in the cerebrospinal fluid and along the leptomeninges.
Recurrent glioblastoma.
The one that comes back.
The most common malignant primary brain tumor in adults, and one of the deadliest. It recurs in the large majority of patients, and treatment options after recurrence are limited, with no single standard approach.
Pediatric brain cancer.
Cancer in a growing brain.
The second most common cancer in children. The treatments that exist can be as hard on a child as the disease itself, and outcomes have improved little in decades.
Leptomeningeal metastases.
Cancer in the cerebrospinal fluid and along the leptomeninges.
When cancer spreads to the leptomeninges and cerebrospinal fluid (CSF), survival is often measured in months. It can be difficult to diagnose, and treatment options remain limited despite advances in systemic and CNS-directed therapies.
Why we focus here.
Cerenome’s CEO on why the company focuses entirely on CNS cancer, and what connects these three diagnoses.
Where Cerenome is active.
Three active ReSPECT™ clinical trials are advancing the investigational therapy REYOBIQ™ across all three diagnoses, alongside CNSide®, in clinical use for leptomeningeal metastases.